新生儿同种免疫性血小板减少症
抗原
抗体
表位
血小板膜糖蛋白
糖蛋白
血小板
分子生物学
重组DNA
单克隆抗体
聚合酶链反应
基因
生物
免疫学
胎儿
遗传学
怀孕
作者
Anthony Poles,Marcin Woźniak,Piers J. Walser,K. Ridgwell,Joan Fitzgerald,Ann Green,Ruth Gilmore,Geoff Lucas
出处
期刊:Transfusion
[Wiley]
日期:2013-01-10
卷期号:53 (9): 1965-1973
被引量:14
摘要
Background Most recently described human platelet antigens ( HPAs ) have been detected in cases of fetomaternal alloimmune thrombocytopenia ( FMAIT ) where the mother has been immunized against a low‐frequency antigen that the fetus has inherited from the father. Low‐frequency antigens are not represented in normal panel platelets ( PLTs ) and antibody detection and identification in such cases requires incubation of maternal serum with paternal PLTs and definition of the causative mutation. Study Design and Methods A suspected case of FMAIT was investigated for PLT ‐specific antibodies using a panel of both HPA ‐typed and paternal PLTs . HPA typing was performed by polymerase chain reaction with sequence‐specific primers and further DNA analysis was performed using direct sequencing of the coding regions of the ITGA 2 B and ITGB 3 genes. Results Maternal antibodies reactive only with paternal PLTs were localized to glycoprotein ( GP ) IIb / IIIa using the monoclonal antibody immobilization of PLT antibody assay. A single‐nucleotide polymorphism was detected in E xon 23 of ITGA 2 B in the father and affected child, which predicted a V 740 L substitution in the mature protein. Recombinant V 740 L mutated GPIIb expressed in HEK 293 cells was specifically recognized by maternal antibodies. The polymorphism was not detected either in the mother or in a cohort of 100 donors. Conclusion The V 740 L polymorphism defines a new low‐frequency antigen implicated in two cases of FMAIT in a single family. Low‐frequency HPAs are clinically important and their elucidation requires both crossmatch studies and gene sequencing in cases where there is strong clinical evidence of FMAIT but initial laboratory investigations do not support the diagnosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI